Brenda Tatiana Camacho Ramirez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brenda Tatiana Camacho Ramirez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bansi Sutariya
Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso-Transmountain
2 shared publications - Camila Sanchez Cruz
Universidad Nacional Autónoma de México
2 shared publications - Carlos David Trevilla Martínez
Universidad Nacional Autónoma de México
2 shared publications - Ernesto Calderon Martinez
Department of Internal Medicine, Texas Tech University Health Science Center At El Paso , 2000 Transmountain, El Paso, TX 79912
2 shared publications - Gabriela Vanessa Flores Monar
Jackson Health System
2 shared publications - Laura A. Gray
Facultad de Medicina de la, Universidad Autónoma de Guadalajara
2 shared publications
Latest Publications
- 11 September 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Survival Determinants in Hypoxic Hepatitis Among Critically Ill Patients: A Systematic Review and Meta-Analysis
Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis or shock liver, is an acute hepatocellular injury caused by an imbalance between hepatic oxygen supply and demand. It develops secondary to cardiac, circulatory, or respiratory failure through reduced hepatic blood flow, systemic hypoxemia, hepatic venous congestion, or impaired cellular oxygen utilization. Although its recognition in critical care has increased, the clinical and biochemical factors distinguishing survivors from non-survivors remain poorly defined. This analysis aimed to characterize these differences among critically ill adults diagnosed with HH. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was pre-registered in PROSPERO (CRD420251180238). A comprehensive search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, CINAHL, and Google Scholar was conducted on July 4, 2025. Eligible studies included critically ill patients diagnosed with HH. Random-effects meta-analyses were performed in R. Results: Of 3236 identified records, five cohort studies comprising 107,346 participants were included. The pooled mean difference in age between survivors and non-survivors was −5.1 years (p = 0.03; I 2 = 23.1%). Mechanical ventilation was associated with lower survival (RR = 0.76; p < 0.01; I 2 = 0.7%), and norepinephrine or other hemodynamic support was associated with lower odds of survival (OR = 0.4; p < 0.01; I 2 = 5.5%). In contrast, lactate, bilirubin, and INR were not significantly associated with survival. Conclusion: Hypoxic hepatitis should be interpreted primarily as a secondary marker of severe cardiac, circulatory, or respiratory failure rather than as an isolated primary driver of mortality. Its occurrence may be associated with increased mortality in critically ill patients; however, the available evidence is limited by the small number of eligible studies and heterogeneity. Further standardized, prospective studies are needed to clarify its independent prognostic significance.
- 11 September 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Survival Determinants in Hypoxic Hepatitis Among Critically Ill Patients: A Systematic Review and Meta-Analysis
Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis or shock liver, is an acute hepatocellular injury caused by an imbalance between hepatic oxygen supply and demand. It develops secondary to cardiac, circulatory, or respiratory failure through reduced hepatic blood flow, systemic hypoxemia, hepatic venous congestion, or impaired cellular oxygen utilization. Although its recognition in critical care has increased, the clinical and biochemical factors distinguishing survivors from non-survivors remain poorly defined. This analysis aimed to characterize these differences among critically ill adults diagnosed with HH. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was pre-registered in PROSPERO (CRD420251180238). A comprehensive search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, CINAHL, and Google Scholar was conducted on July 4, 2025. Eligible studies included critically ill patients diagnosed with HH. Random-effects meta-analyses were performed in R. Results: Of 3236 identified records, five cohort studies comprising 107,346 participants were included. The pooled mean difference in age between survivors and non-survivors was −5.1 years (p = 0.03; I 2 = 23.1%). Mechanical ventilation was associated with lower survival (RR = 0.76; p < 0.01; I 2 = 0.7%), and norepinephrine or other hemodynamic support was associated with lower odds of survival (OR = 0.4; p < 0.01; I 2 = 5.5%). In contrast, lactate, bilirubin, and INR were not significantly associated with survival. Conclusion: Hypoxic hepatitis should be interpreted primarily as a secondary marker of severe cardiac, circulatory, or respiratory failure rather than as an isolated primary driver of mortality. Its occurrence may be associated with increased mortality in critically ill patients; however, the available evidence is limited by the small number of eligible studies and heterogeneity. Further standardized, prospective studies are needed to clarify its independent prognostic significance.
- 3 September 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Hypoxic Hepatitis in Critically Ill Patients: Incidence, Clinical Characteristics, and Outcomes — A Systematic Review and Meta-Analysis
Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis and historically described as shock liver, is an acute liver injury syndrome in critically ill patients characterized by a rapid and marked rise in aminotransferases in the setting of circulatory, cardiac, or respiratory failure, after exclusion of other causes of acute hepatic injury. Despite its clinical relevance, the true incidence and prognostic significance of HH remain unclear. This systematic review and meta-analysis aimed to determine the pooled incidence, mortality, and outcomes of HH in critically ill patients. Methods: This study followed PRISMA guidelines and was registered in PROSPERO (CRD420251088120). A systematic search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, and Google Scholar was conducted on July 4, 2025. Randomized, cohort, and case-control studies involving critically ill adults were included. Primary outcomes were HH incidence and mortality; secondary outcomes included length of stay, organ support, and comparisons with non-HH patients. Random-effects meta-analyses were performed, with heterogeneity assessed using I 2 statistics. Results: Of 3236 records, 25 studies (150,928 patients) met inclusion criteria. The pooled prevalence of HH in ICU patients was 8.3%, and all-cause mortality was 64.0%. Compared with non-HH patients, HH was associated with higher all-cause mortality (RR 2.94). Mechanical ventilation (RR 2.44) and renal replacement therapy (RR 3.80) showed elevated but statistically non-significant associations. Cardiogenic shock, cardiac arrest, and sepsis were the leading reported precipitants. Conclusion: HH affects a substantial proportion of ICU patients and is consistently associated with adverse outcomes and greater organ support use. However, the available evidence supports HH primarily as an associated prognostic marker rather than a proven causal determinant of mortality. Findings should be interpreted cautiously because of high heterogeneity, potential residual confounding, and possible publication bias. Standardized diagnostic criteria and prospective studies evaluating incremental prognostic value beyond established ICU severity scores are needed.
- 3 September 2026
- Published by SAGE Publications in Journal of Intensive Care Medicine
Hypoxic Hepatitis in Critically Ill Patients: Incidence, Clinical Characteristics, and Outcomes — A Systematic Review and Meta-Analysis
Background: Hypoxic hepatitis (HH), also termed ischemic hepatitis and historically described as shock liver, is an acute liver injury syndrome in critically ill patients characterized by a rapid and marked rise in aminotransferases in the setting of circulatory, cardiac, or respiratory failure, after exclusion of other causes of acute hepatic injury. Despite its clinical relevance, the true incidence and prognostic significance of HH remain unclear. This systematic review and meta-analysis aimed to determine the pooled incidence, mortality, and outcomes of HH in critically ill patients. Methods: This study followed PRISMA guidelines and was registered in PROSPERO (CRD420251088120). A systematic search of PubMed, Scopus, Web of Science, EMBASE, Cochrane, LILACS, CNKI, and Google Scholar was conducted on July 4, 2025. Randomized, cohort, and case-control studies involving critically ill adults were included. Primary outcomes were HH incidence and mortality; secondary outcomes included length of stay, organ support, and comparisons with non-HH patients. Random-effects meta-analyses were performed, with heterogeneity assessed using I 2 statistics. Results: Of 3236 records, 25 studies (150,928 patients) met inclusion criteria. The pooled prevalence of HH in ICU patients was 8.3%, and all-cause mortality was 64.0%. Compared with non-HH patients, HH was associated with higher all-cause mortality (RR 2.94). Mechanical ventilation (RR 2.44) and renal replacement therapy (RR 3.80) showed elevated but statistically non-significant associations. Cardiogenic shock, cardiac arrest, and sepsis were the leading reported precipitants. Conclusion: HH affects a substantial proportion of ICU patients and is consistently associated with adverse outcomes and greater organ support use. However, the available evidence supports HH primarily as an associated prognostic marker rather than a proven causal determinant of mortality. Findings should be interpreted cautiously because of high heterogeneity, potential residual confounding, and possible publication bias. Standardized diagnostic criteria and prospective studies evaluating incremental prognostic value beyond established ICU severity scores are needed.